Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 22 recruiting now early-phase tilt

Soft Tissue Sarcoma: early-phase trial registry

22 of 56 indexed Soft Tissue Sarcoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #252 of 28,707 conditions by registered trial count.

56 US clinical trials · 22 currently recruiting · #252 of 28,707 conditions by registered trial count

Soft Tissue Sarcoma: 56 US clinical trials tracked, 22 recruiting.

Soft Tissue Sarcoma is the subject of 56 registered US clinical trials on ClinicalTrials.gov, 22 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 4 of these trials.

Enrollment posture brief

Registry condition soft-tissue-sarcoma

OPEN 22 | RECR 39% | LATE 2 | EARLY 43 | RANK #252 | SPON 4

Nearest open-share peer: Eye Diseases (39% recruiting · 28 trials)

Sleep Disturbance56.1%Gynecologic Cancer48.2%Trauma43.9%Soft Tissue Sarcoma (this)39%Ocular Hypertension21.1%
Open-enrollment share among volume-matched conditions near Soft Tissue Sarcoma

Soft Tissue Sarcoma lists 22 open slots (39% of 56 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Soft Tissue Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Soft Tissue Sarcoma recruits in line with its size-band peers.

    22 of 56 indexed trials (39.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Soft Tissue Sarcoma trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 4 of 56 trials (7.1%). 42 distinct sponsors appear on at least one study for this condition label.

  3. Most Soft Tissue Sarcoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 56 trials that report a genuine target (sentinel values excluded). 47 of those (83.9%) plan for fewer than 100 participants.

  4. Soft Tissue Sarcoma research is mostly interventional.

    52 interventional and 4 observational studies make up this index (92.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 123Phase 220Phase 32

Phase Distribution

PhaseTrial count
Phase 1 23
Phase 2 20
Phase 3 2

Named interventions

Most-linked intervention names on Soft Tissue Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Gemcitabine Drug
4 trials
Talimogene Laherparepvec Drug
3 trials
Radiotherapy Radiation
3 trials
Radiation Therapy Radiation
3 trials
Doxorubicin Drug
3 trials
Docetaxel Drug
3 trials
Olaratumab Drug
2 trials
ADI PEG20 Drug
2 trials

US sites by state

Facility locations filed on Soft Tissue Sarcoma trials. A trial with sites in several states counts in each.

New York 19 trials
California 17 trials
Texas 12 trials
Florida 12 trials
Pennsylvania 10 trials
Missouri 10 trials
Iowa 9 trials
Ohio 7 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Soft Tissue Sarcoma page

56 registered trials, 22 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Soft Tissue Sarcoma condition card totals 56 registered trials; most-linked intervention Gemcitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.